Kyntra Bio (KYNB) Payables (2014 - 2026)

Kyntra Bio has disclosed Payables across 13 years of filings, most recently posting $7.5 million for Q2 2026.

• In Q2 2026, Payables fell 28.32% year-over-year to $7.5 million; the TTM figure through Jun 2026 stood at $7.5 million (down 28.32% YoY), while the FY2025 annual figure was $3.7 million, down 26.05% from the prior year.
• Payables came in at $7.5 million for Q2 2026 at Kyntra Bio, up from $5.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $71.3 million in Q1 2023 to a low of $3.7 million in Q4 2025.
• Average Payables over 5 years is $16.8 million, with a median of $10.2 million recorded in 2024.
• Year-over-year, Payables soared 96.08% in 2023 and sank 93.89% in 2024.
• Over 5 years, Payables stood at $30.8 million in 2022, then sank by 48.7% to $15.8 million in 2023, then sank by 67.9% to $5.1 million in 2024, then retreated by 26.05% to $3.7 million in 2025, then surged by 100.53% to $7.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $7.5 million in Q2 2026, $5.1 million in Q1 2026, and $3.7 million in Q4 2025.